The Risk of Venous Thromboembolism with Different Generation of Oral Contraceptives; a Systematic Review and Meta-Analysis

Overview

Journal Emerg (Tehran)

Specialty Emergency Medicine

Date 2015 Oct 24

PMID 26495334

Citations 14

Authors

Alireza Baratloo

Saeed Safari

Alaleh Rouhipour

Behrooz Hashemi

Farhad Rahmati

Maryam Motamedi

Mohammadmehdi Forouzanfar

Pauline Haroutunian

Affiliations

Soon will be listed here.

Abstract

Introduction: Oral contraceptives (OCs) are considered as one of the most common risk factor of venous thromboembolism (VTE) in childbearing age. Some of the recent researches indicate that the odds of VTE may be even higher with newer generations of OCs. The present meta-analysis was designed to evaluate the effect of different generation of OCs on the occurrence of VTE.

Methods: Two researchers independently ran a thorough search in Pubmed, ISI Web of Science, EMBASE, CINAHL and Scopus databases regarding study keywords including thromboembolic event, thromboembolism, embolism, thromboembolic, thrombotic and thrombosis, combined with oral contraceptive. The outcomes were the incidence of diagnosed thromboembolism, such as deep vein thrombosis, pulmonary embolism and cerebral venous thrombosis. Based on the heterogeneity of the studies, random effect model was used and pooled odds ratio was reported.

Results: Three cohort and 17 case-control studies with 13,265,228 subjects were entered into meta-analysis. Analysis showed that the odds of VTE in women taking OCs are more than three-fold (OR=3.13; 95% CI: 2.61-3.65). The risk of VTE in women taking first-, second- and third-generation OCs are 3.5 fold (OR=3.48; 95% CI: 2.01-4.94), 3 fold (OR=3.08; 95% CI: 2.43-3.74) and 4.3 fold (OR=4.35; CI: 3.69‒5.01), respectively.

Conclusion: It seems that the risk of VTE is not same between different generations of OCs, so that third-generation has highest risk. Taking second and third-generation OCs increases the risk of VTE up to 3 and 4.3 fold, respectively. The researchers of the present study suggest that more trials be designed in relation to the effect of newer generations of OCs in different communities.

Citing Articles

Combined oral contraceptives may activate the contact system in healthy women.

Strandberg J, Gade I, Palarasah Y, Gram J, Kristensen S, Sidelmann J Res Pract Thromb Haemost. 2023; 7(2):100118.

PMID: 37063763 PMC: 10099323. DOI: 10.1016/j.rpth.2023.100118.

Association of Hormonal Contraceptive Use With Adverse Health Outcomes: An Umbrella Review of Meta-analyses of Randomized Clinical Trials and Cohort Studies.

Brabaharan S, Veettil S, Kaiser J, Raja Rao V, Wattanayingcharoenchai R, Maharajan M JAMA Netw Open. 2022; 5(1):e2143730.

PMID: 35029663 PMC: 8760614. DOI: 10.1001/jamanetworkopen.2021.43730.

Severity of Depressive Symptoms is Associated with Venous Thromboembolism in Hospitalized Patients with a Major Depressive Episode.

Yoshizawa K, Takeshima M, Ishino S, Ogasawara M, Fujiwara D, Itoh Y Neuropsychiatr Dis Treat. 2021; 17:2955-2963.

PMID: 34584413 PMC: 8464371. DOI: 10.2147/NDT.S331409.

The comparative effectiveness of 55 interventions in obese patients with polycystic ovary syndrome: A network meta-analysis of 101 randomized trials.

Abdel-Maboud M, Menshawy A, Hasabo E, Abdelraoof M, Alshandidy M, Eid M PLoS One. 2021; 16(7):e0254412.

PMID: 34280195 PMC: 8289030. DOI: 10.1371/journal.pone.0254412.

Analysis of Media Outlets on Women's Health: Thematic and Quantitative Analyses Using Twitter.

Alvarez-Mon M, Donat-Vargas C, Llavero-Valero M, Gea A, Alvarez-Mon M, Martinez-Gonzalez M Front Public Health. 2021; 9:644284.

PMID: 34136450 PMC: 8200480. DOI: 10.3389/fpubh.2021.644284.

References

Rott H . Thrombotic risks of oral contraceptives. Curr Opin Obstet Gynecol. 2012; 24(4):235-40. DOI: 10.1097/GCO.0b013e328355871d. View

Hosseini M, Yousefifard M, Taslimi S, Sohanaki H, Nourijelyani K, Asgari F . Trend of blood cholesterol level in Iran: results of four national surveys during 1991-2008. Acta Med Iran. 2013; 51(9):642-51. View

Wu C, Grandi S, Filion K, Abenhaim H, Joseph L, Eisenberg M . Drospirenone-containing oral contraceptive pills and the risk of venous and arterial thrombosis: a systematic review. BJOG. 2013; 120(7):801-10. DOI: 10.1111/1471-0528.12210. View

Heinemann L, Lewis M, Assmann A, Thiel C . Case-control studies on venous thromboembolism: bias due to design? A methodological study on venous thromboembolism and steroid hormone use. Contraception. 2002; 65(3):207-14. DOI: 10.1016/s0010-7824(01)00309-2. View

Suissa S, Spitzer W, Rainville B, Cusson J, Lewis M, Heinemann L . Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. Hum Reprod. 2000; 15(4):817-21. DOI: 10.1093/humrep/15.4.817. View

Jick S, Hernandez R . Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ. 2011; 342:d2151. PMC: 3081040. DOI: 10.1136/bmj.d2151. View

Miller J, Chan B, Nelson H . Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2002; 136(9):680-90. DOI: 10.7326/0003-4819-136-9-200205070-00011. View

Urrutia R, Coeytaux R, McBroom A, Gierisch J, Havrilesky L, Moorman P . Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis. Obstet Gynecol. 2013; 122(2 Pt 1):380-389. DOI: 10.1097/AOG.0b013e3182994c43. View

. Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser. 1998; 877:i-vii, 1-89. View

10.

Bergendal A, Bremme K, Hedenmalm K, Larfars G, Odeberg J, Persson I . Risk factors for venous thromboembolism in pre-and postmenopausal women. Thromb Res. 2012; 130(4):596-601. DOI: 10.1016/j.thromres.2012.05.024. View

11.

Bloemenkamp K, Rosendaal F, Helmerhorst F, Vandenbroucke J . Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med. 2000; 160(1):49-52. DOI: 10.1001/archinte.160.1.49. View

12.

Austin H, Lally C, Benson J, Whitsett C, Hooper W, Key N . Hormonal contraception, sickle cell trait, and risk for venous thromboembolism among African American women. Am J Obstet Gynecol. 2009; 200(6):620.e1-3. DOI: 10.1016/j.ajog.2009.01.038. View

13.

Stroup D, Berlin J, Morton S, Olkin I, Williamson G, Rennie D . Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283(15):2008-12. DOI: 10.1001/jama.283.15.2008. View

14.

Smith N, Heckbert S, Lemaitre R, Reiner A, Lumley T, Weiss N . Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA. 2004; 292(13):1581-7. DOI: 10.1001/jama.292.13.1581. View

15.

Heinemann L, Dinger J, Assmann A, Minh T . Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare". Contraception. 2010; 81(5):401-7. DOI: 10.1016/j.contraception.2009.12.014. View

16.

Rosendaal F . Risk factors for venous thrombosis: prevalence, risk, and interaction. Semin Hematol. 1997; 34(3):171-87. View

17.

Wu O, Robertson L, Langhorne P, Twaddle S, Lowe G, Clark P . Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost. 2005; 94(1):17-25. DOI: 10.1160/TH04-11-0759. View

18.

Lidegaard O, Edstrom B, Kreiner S . Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception. 2002; 65(3):187-96. DOI: 10.1016/s0010-7824(01)00307-9. View

19.

Lidegaard O, Nielsen L, Skovlund C, Skjeldestad F, Lokkegaard E . Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ. 2011; 343:d6423. PMC: 3202015. DOI: 10.1136/bmj.d6423. View

20.

Aznar J, Vaya A, Estelles A, Mira Y, Segui R, Villa P . Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives. Haematologica. 2000; 85(12):1271-6. View